• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money

cafead

Administrator
Staff member
  • cafead   Mar 03, 2022 at 12:12: PM
via Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes as the Cambridge, Massachusetts-based drug company tries to overcome challenges in selling a new and controversial treatment for Alzheimer's disease, as well as recover from setbacks to its business elsewhere.

article source
 

<